Wall Street analyst estimates for Lexeo Therapeutics, Inc. Common Stock (LXEO): consensus price target, buy/hold/sell recommendations and forecasts for revenue, EPS and EBITDA for the upcoming fiscal years.
Lexeo Therapeutics, Inc. is a genetic medicine firm currently in the clinical development phase, dedicated to addressing both inherited and acquired medical conditions. Its robust pipeline features several gene therapy candidates.
Recent Earnings Surprises
| Date | EPS Actual | EPS Est. | vs Est. |
|---|---|---|---|
| 2026-12-14 | $-0.33 | ||
| 2026-08-12 | $-0.30 | $-0.29 | -5.2% |
| 2026-05-11 | $-0.25 | $-0.29 | +13.8% |
| 2026-03-30 | $-0.27 | $-0.32 | +15.6% |
| 2025-11-05 | $-0.33 | $-0.48 | +31.2% |
| 2025-08-14 | $-0.60 | $-0.64 | +6.3% |
| 2025-05-12 | $-0.99 | $-0.80 | -23.7% |
| 2025-03-24 | $-0.78 | $-0.87 | +10.3% |
Valuation Ratios
| Price / Book | 1.52 |
| EV / EBITDA | -3.00 |
| Dividend Yield | 0.00% |
Income Statement (10y)
| Year | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Revenue | $518476 | $1.7M | $654000 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | $518476 | $1.7M | $654000 | 0 | 0 | 0 |
| Research & Development | $4.3M | $45.1M | $49.2M | $53.1M | $74.1M | $63.8M |
| Selling, General & Admin | $787499 | $7.2M | $12.0M | $15.4M | $31.7M | $45.5M |
| Operating Expenses | $5.1M | $52.3M | $61.2M | $68.5M | $105.8M | $109.3M |
| Operating Income | -$4.6M | -$50.6M | -$60.5M | -$68.5M | -$105.8M | -$109.3M |
| EBITDA | -$4.6M | -$50.6M | -$58.0M | -$64.3M | -$96.2M | -$97.7M |
| Interest Expense | $147150 | 0 | $91000 | $205000 | $114000 | $206000 |
| Pre-tax Income | -$5.2M | -$50.6M | -$59.3M | -$66.4M | -$98.3M | -$100.0M |
| Income Tax | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Income | -$5.2M | -$50.6M | -$59.3M | -$66.4M | -$98.3M | -$100.0M |
| EPS | $-0.20 | $-2.01 | $-2.36 | $-2.49 | $-3.09 | $-1.86 |
| EPS (Diluted) | $-0.20 | $-2.01 | $-2.40 | $-2.49 | $-3.09 | $-1.86 |
| Shares Outstanding (Diluted) | $25.2M | $25.2M | $25.2M | $26.6M | $31.8M | $53.6M |
Price
| Price | $4.16 |
| Market Cap | $327M |
| Exchange | NASDAQ |
| Country | US |
Related companies: AMRN · CAPR · CTNM · DBVT · KYTX · LRMR · MREO
Explore sector: Healthcare · Biotechnology
More sections of LXEO: Overview · Financials · Valuation · Statistics · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks